Ordering Information:

To place an order call
1-800-299-3431.

Product Website

Material Safety Data Sheet (MSDS) (PDF)

Full Prescribing Information including boxed WARNING
regarding serious cardiopulmonary reactions (PDF)

Revised Healthcare Provider Letter (PDF)

Important Safety Information:

Do not administer DEFINITY® to patients with known or suspected cardiac shunts (right-to-left, bi-directional or transient right-to-left), or hypersensitivity to perflutren.  Do not administer DEFINITY® by intra-arterial injection.

In postmarketing use, uncommon but serious reactions observed during or shortly following perflutren-containing microsphere administration included fatal cardiac or respiratory arrest, loss of consciousness, convulsions, symptomatic arrhythmias (atrial fibrillation, supraventricular tachycardia, ventricular tachycardia or fibrillation), hypotension, respiratory distress or cardiac ischemia (see ADVERSE REACTIONS).  The risk for these reactions may be increased among patients with pulmonary hypertension or unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, serious ventricular arrhythmias or respiratory failure, including patients receiving mechanical ventilation).  In the absence of these underlying conditions, observe patients closely during and following DEFINITY® administration.

Always have cardiopulmonary resuscitation personnel and equipment readily available prior to DEFINITY® administration and monitor all patients for acute reactions.

INDICATIONS

Activated DEFINITY® (Perflutren Lipid Microsphere) Injectable Suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

The safety and efficacy of DEFINITY® with exercise stress or pharmacologic stress testing have not been established.

Please see Full Prescribing Information, including boxed WARNING regarding serious cardiopulmonary reactions.

Ordering Information:

To place an order call
1-800-299-3431.

Important DEFINITY® Safety Information:

Do not administer DEFINITY® to patients with known or suspected cardiac shunts (right-to-left, bi-directional or transient right-to-left), or hypersensitivity to perflutren.  Do not administer DEFINITY® by intra-arterial injection.

In postmarketing use, uncommon but serious reactions observed during or shortly following perflutren-containing microsphere administration included fatal cardiac or respiratory arrest, loss of consciousness, convulsions, symptomatic arrhythmias (atrial fibrillation, supraventricular tachycardia, ventricular tachycardia or fibrillation), hypotension, respiratory distress or cardiac ischemia (see ADVERSE REACTIONS).  The risk for these reactions may be increased among patients with pulmonary hypertension or unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, serious ventricular arrhythmias or respiratory failure, including patients receiving mechanical ventilation).  In the absence of these underlying conditions, observe patients closely during and following DEFINITY® administration.

Always have cardiopulmonary resuscitation personnel and equipment readily available prior to DEFINITY® administration and monitor all patients for acute reactions.

INDICATIONS

Activated DEFINITY® (Perflutren Lipid Microsphere) Injectable Suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

The safety and efficacy of DEFINITY® with exercise stress or pharmacologic stress testing have not been established.

Please see Full Prescribing Information, including boxed WARNING regarding serious cardiopulmonary reactions.

Ordering Information:

To place an order call
1-800-299-3431.

Important DEFINITY® Safety Information:

Do not administer DEFINITY® to patients with known or suspected cardiac shunts (right-to-left, bi-directional or transient right-to-left), or hypersensitivity to perflutren.  Do not administer DEFINITY® by intra-arterial injection.

In postmarketing use, uncommon but serious reactions observed during or shortly following perflutren-containing microsphere administration included fatal cardiac or respiratory arrest, loss of consciousness, convulsions, symptomatic arrhythmias (atrial fibrillation, supraventricular tachycardia, ventricular tachycardia or fibrillation), hypotension, respiratory distress or cardiac ischemia (see ADVERSE REACTIONS).  The risk for these reactions may be increased among patients with pulmonary hypertension or unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, serious ventricular arrhythmias or respiratory failure, including patients receiving mechanical ventilation).  In the absence of these underlying conditions, observe patients closely during and following DEFINITY® administration.

Always have cardiopulmonary resuscitation personnel and equipment readily available prior to DEFINITY® administration and monitor all patients for acute reactions.

INDICATIONS

Activated DEFINITY® (Perflutren Lipid Microsphere) Injectable Suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

The safety and efficacy of DEFINITY® with exercise stress or pharmacologic stress testing have not been established.

Please see Full Prescribing Information, including boxed WARNING regarding serious cardiopulmonary reactions.

Ordering Information:

To place an order call
1-800-299-3431.

Product Website

Material Safety Data Sheet (MSDS) (PDF)

Prescribing Information (PDF)

Important Safety Information:

Exercise and pharmacologic stress testing should be performed only
under the supervision of a qualified physician. Cardiolite® has been
rarely associated with acute severe allergic events of angioedema
and urticaria. The most frequently reported adverse events include
headache, chest pain/angina, ST segment changes on
ECG, nausea, and abnormal taste and smell.

Ordering Information:

To place an order call
1-800-299-3431.

• As the leader in the production of Tc99m generators, we ensure that
  our manufacturing systems reflect the most advanced technology
  and the strictest of quality standards.
• Tc99m generators are calibrated on the same day of manufacturing.
• Manufacturing days are Monday, Tuesday, Thursday, Friday and Saturday

Prescribing Information (PDF)

Material Safety Data Sheet (MSDS) (PDF)

TechneLite® Tc99m Yield Chart SUNDAY (PDF)

TechneLite® Tc99m Yield Chart MONDAY-FRIDAY (PDF)

Important Safety Information:

Allergic reactions including anaphylaxis have been reported infrequently.

Ordering Information:

To place an order call
1-800-299-3431.

The SPECT brain perfusion agent with 6-hour stability after preparation

• Allows for flexible patient scheduling
• Allows for convenient unit dosing

Prescribing Information (PDF)

Vial A Material Safety Data Sheet (MSDS) (PDF)

Vial B Material Safety Data Sheet (MSDS) (PDF)

Important Safety Information:

NEUROLITE® must be used with caution in patients with renal or hepatic impairment. Reported adverse events are rare, but may include headache, seizure, syncope, cardiac failure, hypertension and apnea/cyanosis.

Ordering Information:

• Selection of sizes that remain the most extensive
• Efficient 2 mCi/ml concentration at label calibration
• Price per mCi ordering
• More precise ordering
• Record of on-time delivery nationwide
• Easy to order
• Easy to use

Prescribing Information (PDF)

Material Safety Data Sheet (MSDS) (PDF)

Important Safety Information:

Adverse patient reaction to Tl 201 is extremely rare. Rashes and/or temporary
low blood pressure have occurred, which have been treated with no further
reported complications.

Ordering Information:

To place an order call
1-800-299-3431.

The Greatest Choice of Vials Available for Flexible Ordering and Reduced Waste

• From the first company to offer Gallium Citrate Ga 67
• High purity for optimal image quality; at time of calibration:
  • not less than 99.89% Ga 67
  • less than 0.01% Ga 66
  • less than 0.1% other radiocontaminants
• Unsurpassed record of on-time delivery nationwide

Prescribing Information (PDF)

Material Safety Data Sheet (MSDS) (PDF)

Important Safety Information:

Adverse reactions are rare and include allergic reactions, skin rash and nausea.

Convenience and Safety:

Widest selection of vial sizes to maximize number of usable doses and reduce waste

Pre-calibration delivery and seven-day post-calibration expiration provide ordering
flexibility to meet scheduling demands

2mCi/ml concentration at calibration allows easy injection pre- and post-calibration

Ordering Information:

To place an order call
1-800-299-3431.

** Also may be ordered in 30, 40, 50 and 100 mCi's, with a ten-day lead time **

• Used in millions of studies
• Provides functional information during first breath, equilibrium and wash-out phases
• Record of on-time delivery nationwide

Prescribing Information (PDF)

Material Safety Data Sheet (MSDS) (PDF)

Important Safety Information:

Adverse reactions related to the use of this agent have not been reported to date.

Convenience and Safety:

Single-dose dispensing system reduces radiation exposure

Shielded vial storage and transfer minimizes radiation exposure

Pre-calibration delivery and 10-day post-calibration expiration provide ordering flexibility to meet scheduling demands